- Home
- BHC vs CNTA Comparison
BHC vs CNTA Comparison
Compare BHC & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHC
- CNTA
- Stock Information
- Founded
- BHC N/A
- CNTA 2020
- Country
- BHC Canada
- CNTA United Kingdom
- Employees
- BHC N/A
- CNTA N/A
- Industry
- BHC Biotechnology: Pharmaceutical Preparations
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- BHC Health Care
- CNTA Health Care
- Exchange
- BHC Nasdaq
- CNTA Nasdaq
- Market Cap
- BHC 2.6B
- CNTA 2.2B
- IPO Year
- BHC N/A
- CNTA 2021
- Fundamental
- Price
- BHC $5.10
- CNTA $12.30
- Analyst Decision
- BHC Hold
- CNTA Strong Buy
- Analyst Count
- BHC 5
- CNTA 9
- Target Price
- BHC $7.20
- CNTA $25.63
- AVG Volume (30 Days)
- BHC 3.0M
- CNTA 1.2M
- Earning Date
- BHC 04-30-2025
- CNTA 05-12-2025
- Dividend Yield
- BHC N/A
- CNTA N/A
- EPS Growth
- BHC N/A
- CNTA N/A
- EPS
- BHC N/A
- CNTA N/A
- Revenue
- BHC $9,625,000,000.00
- CNTA N/A
- Revenue This Year
- BHC $4.76
- CNTA N/A
- Revenue Next Year
- BHC $2.05
- CNTA N/A
- P/E Ratio
- BHC N/A
- CNTA N/A
- Revenue Growth
- BHC 9.91
- CNTA N/A
- 52 Week Low
- BHC $3.96
- CNTA $7.75
- 52 Week High
- BHC $9.85
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- BHC 39.07
- CNTA 40.90
- Support Level
- BHC $4.28
- CNTA $11.50
- Resistance Level
- BHC $5.45
- CNTA $12.82
- Average True Range (ATR)
- BHC 0.41
- CNTA 1.21
- MACD
- BHC -0.06
- CNTA 0.03
- Stochastic Oscillator
- BHC 37.44
- CNTA 50.95
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.